Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Alzheimer's Disease

  Free Subscription

Articles published in Lancet Neurol

Retrieve available abstracts of 46 articles:
HTML format

Single Articles

    March 2024
  1. FRISONI GB, Festari C, Massa F, Cotta Ramusino M, et al
    European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders.
    Lancet Neurol. 2024;23:302-312.
    PubMed     Abstract available

    Dementia diagnosis in the anti-amyloid era.
    Lancet Neurol. 2024;23:219.

    February 2024
  3. CHAPLEAU M, La Joie R, Yong K, Agosta F, et al
    Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis.
    Lancet Neurol. 2024;23:168-177.
    PubMed     Abstract available

  4. REIMAN EM, Cummings JL, Langbaum JB, Mattke S, et al
    A chance to prevent Alzheimer's disease sooner than you think.
    Lancet Neurol. 2024;23:144-145.

  5. BEJANIN A, Villain N
    Posterior cortical atrophy: new insights into treatments and biomarkers for Alzheimer's disease.
    Lancet Neurol. 2024;23:127-128.

    January 2024
  6. DELRIEU J, Andrieu S, Vellas B
    Dementia research in 2023: the year of anti-amyloid immunotherapy.
    Lancet Neurol. 2024;23:13-15.

    December 2023
    Powerful series profiles rare forms of dementia.
    Lancet Neurol. 2023;22:1112.

    November 2023
  8. SCHLEPCKOW K, Morenas-Rodriguez E, Hong S, Haass C, et al
    Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer's disease.
    Lancet Neurol. 2023;22:1048-1060.
    PubMed     Abstract available

    September 2023
  9. JAGUST WJ, Teunissen CE, DeCarli C
    The complex pathway between amyloid beta and cognition: implications for therapy.
    Lancet Neurol. 2023;22:847-857.
    PubMed     Abstract available

    July 2023
  10. BELDER CRS, Schott JM, Fox NC
    Preparing for disease-modifying therapies in Alzheimer's disease.
    Lancet Neurol. 2023 Jul 14:S1474-4422(23)00274.

    Complexity is the simple truth about Alzheimer's disease.
    Lancet Neurol. 2023 Jul 13:S1474-4422(23)00176.

    June 2023
    Treatment for Alzheimer's disease: time to get ready.
    Lancet Neurol. 2023;22:455.

  13. MASON M, Bacioglu M, Vivacqua G, Spillantini MG, et al
    Targeting tau degradation: a viable therapeutic approach?
    Lancet Neurol. 2023;22:462-464.

    May 2023
  14. LANGWORTH-GREEN C, Patel S, Jaunmuktane Z, Jabbari E, et al
    Chronic effects of inflammation on tauopathies.
    Lancet Neurol. 2023;22:430-442.
    PubMed     Abstract available

    February 2023
  15. MEAD S, Fox NC
    Lecanemab slows Alzheimer's disease: hope and challenges.
    Lancet Neurol. 2023;22:106-108.

    January 2023
  16. BOERWINKLE AH, Gordon BA, Wisch J, Flores S, et al
    Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study.
    Lancet Neurol. 2023;22:55-65.
    PubMed     Abstract available

  17. FORTEA J, Quiroz YT, Ryan NS
    Lessons from Down syndrome and autosomal dominant Alzheimer's disease.
    Lancet Neurol. 2023;22:5-6.

    November 2022
  18. HARDY J, de Strooper B, Escott-Price V
    Diabetes and Alzheimer's disease: shared genetic susceptibility?
    Lancet Neurol. 2022;21:962-964.

    October 2022
  19. JACK CR JR
    Advances in Alzheimer's disease research over the past two decades.
    Lancet Neurol. 2022;21:866-869.

    May 2022
  20. OSSENKOPPELE R, van der Kant R, Hansson O
    Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials.
    Lancet Neurol. 2022 May 25. pii: S1474-4422(22)00168.
    PubMed     Abstract available

    April 2022
  21. MORENAS-RODRIGUEZ E, Li Y, Nuscher B, Franzmeier N, et al
    Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.
    Lancet Neurol. 2022;21:329-341.
    PubMed     Abstract available

  22. SMIRNOV D, Galasko D
    Dynamics of neuroinflammation in Alzheimer's disease.
    Lancet Neurol. 2022;21:297-298.

    February 2022
  23. CHHATWAL JP, Schultz SA, McDade E, Schultz AP, et al
    Variant-dependent heterogeneity in amyloid beta burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study.
    Lancet Neurol. 2022;21:140-152.
    PubMed     Abstract available

  24. FRISONI GB, Lathuiliere A
    From patients to disease: the difficult case of Alzheimer's.
    Lancet Neurol. 2022;21:105-106.

    January 2022
    2021 marks a new era for Alzheimer's therapeutics.
    Lancet Neurol. 2022;21:3-4.

    December 2021
  26. MEAD S, Evans T
    Safe laboratory management of prions and proteopathic seeds.
    Lancet Neurol. 2021;20:981.

    November 2021
  27. TEUNISSEN CE, Verberk IMW, Thijssen EH, Vermunt L, et al
    Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.
    Lancet Neurol. 2021 Nov 24. pii: S1474-4422(21)00361.
    PubMed     Abstract available

  28. FORTEA J, Zaman SH, Hartley S, Rafii MS, et al
    Alzheimer's disease associated with Down syndrome: a genetic form of dementia.
    Lancet Neurol. 2021;20:930-942.
    PubMed     Abstract available

  29. KEHOE PG, Turner N, Howden B, Jarutyte L, et al
    Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet Neurol. 2021;20:895-906.
    PubMed     Abstract available

    The link between blood pressure and Alzheimer's disease.
    Lancet Neurol. 2021;20:878-879.

    September 2021
  31. THIJSSEN EH, La Joie R, Strom A, Fonseca C, et al
    Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
    Lancet Neurol. 2021;20:739-752.
    PubMed     Abstract available

  32. PARNETTI L, Filippo MD, Gaetani L
    A blood test for Alzheimer's disease: a step forward.
    Lancet Neurol. 2021;20:691-693.

    August 2021
  33. FAGAN AM, Henson RL, Li Y, Boerwinkle AH, et al
    Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.
    Lancet Neurol. 2021;20:615-626.
    PubMed     Abstract available

  34. FRISONI GB, Hansson O
    Management of Alzheimer's disease takes a leap forward.
    Lancet Neurol. 2021;20:586-587.

  35. CARMONA-IRAGUI M, Alcolea D, Barroeta I, Videla L, et al
    Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study.
    Lancet Neurol. 2021;20:605-614.
    PubMed     Abstract available

    July 2021
    A contentious FDA ruling for Alzheimer's disease.
    Lancet Neurol. 2021 Jul 5. pii: S1474-4422(21)00215.

  37. BURNS DK, Alexander RC, Welsh-Bohmer KA, Culp M, et al
    Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet Neurol. 2021;20:537-547.
    PubMed     Abstract available

    April 2021
  38. DUBOIS B, Villain N, Frisoni GB, Rabinovici GD, et al
    Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group.
    Lancet Neurol. 2021 Apr 29. pii: S1474-4422(21)00066.
    PubMed     Abstract available

    The changing definition of Alzheimer's disease.
    Lancet Neurol. 2021 Apr 29. pii: S1474-4422(21)00077.

    March 2021
  40. GRAFF-RADFORD J, Yong KXX, Apostolova LG, Bouwman FH, et al
    New insights into atypical Alzheimer's disease in the era of biomarkers.
    Lancet Neurol. 2021;20:222-234.
    PubMed     Abstract available

    January 2021
  41. SERRANO-POZO A, Das S, Hyman BT
    APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches.
    Lancet Neurol. 2021;20:68-80.
    PubMed     Abstract available

  42. KIVIPELTO M, Mangialasche F
    Dementia research in 2020: moving forward despite the COVID-19 pandemic.
    Lancet Neurol. 2021;20:3-5.

    Rapid drug access and scientific rigour: a delicate balance.
    Lancet Neurol. 2021;20:1.

    November 2020
  44. CHETELAT G, Arbizu J, Barthel H, Garibotto V, et al
    Amyloid-PET and (18)F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias.
    Lancet Neurol. 2020;19:951-962.
    PubMed     Abstract available

  45. ISAACS JD, Boenink M
    Biomarkers for dementia: too soon for routine clinical use.
    Lancet Neurol. 2020;19:884-885.

    October 2020
  46. LAUWERS E, Lalli G, Brandner S, Collinge J, et al
    Potential human transmission of amyloid beta pathology: surveillance and risks.
    Lancet Neurol. 2020;19:872-878.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge.